Want to see IN:ZYDUSWELL full AI Analyst Report?
ZYDUSWELL Stock Chart & Stats
₹424.90
-₹21.60(-1.10%)
At close: 4:00 PM EST
₹424.90
-₹21.60(-1.10%)
Day’s Range― - ―
52-Week Range₹357.55 - ₹610.95
Previous CloseN/A
Volume6.77K
Average Volume (3M)15.16K
Market Cap
₹167.16B
Enterprise Value₹166.44K
Total Cash (Recent Filing)₹1.15B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)89.4
Beta0.84
Next Earnings
Nov 14, 2026EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend Yield0.23%
Share Statistics
EPS (TTM)5.92
Shares Outstanding318,160,700
10 Day Avg. Volume9,092
30 Day Avg. Volume15,161
Financial Highlights & Ratios
PEG Ratio-1.59
Price to Book (P/B)2.33
Price to Sales (P/S)3.42
P/FCF Ratio345.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.46
Revenue Forecast (FY)₹53.12B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthThe sharp acceleration indicates stronger demand, distribution, or product adoption across the wellness portfolio. If sustained, higher scale can improve brand reach and provide a broader base for rebuilding profitability.
Branded, Diversified Wellness PortfolioA portfolio spanning recurring consumer-health and wellness needs can support repeat purchases and reduce dependence on a single category. Brand-led sales and broad distribution also provide a platform for product extensions and continued market penetration.
Positive Free Cash FlowAlthough substantially below the prior year, positive free cash flow shows the business still generated cash after investment requirements. This provides some internal funding capacity for operations and brand support without relying entirely on external capital.
Bears Say
Sharp Margin CompressionThe margin reset indicates that rapid sales growth is not currently translating into comparable earnings growth. Higher costs, weaker pricing, or adverse mix could constrain future profit conversion unless management restores operating leverage.
Higher LeverageThe substantial increase from a previously lightly leveraged position reduces financial flexibility and may raise interest or refinancing exposure. It also limits the company’s capacity to absorb prolonged margin pressure or invest aggressively.
Deteriorating Cash ConversionLower operating and free cash flow despite strong revenue growth points to weaker cash conversion, potentially from working-capital pressure or higher cash costs. Persistent deterioration could restrict reinvestment and increase dependence on debt.
Zydus Wellness Limited News
ZYDUSWELL FAQ
What was Zydus Wellness Limited’s price range in the past 12 months?
Zydus Wellness Limited lowest stock price was ₹357.55 and its highest was ₹610.95 in the past 12 months.
What is Zydus Wellness Limited’s market cap?
Zydus Wellness Limited’s market cap is ₹167.16B.
When is Zydus Wellness Limited’s upcoming earnings report date?
Zydus Wellness Limited’s upcoming earnings report date is Nov 14, 2026 which is in 78 days.
How were Zydus Wellness Limited’s earnings last quarter?
Zydus Wellness Limited released its earnings results on Aug 04, 2026. The company reported ₹3.7 earnings per share for the quarter, missing the consensus estimate of ₹3.933 by -₹0.233.
Is Zydus Wellness Limited overvalued?
According to Wall Street analysts Zydus Wellness Limited’s price is currently Overvalued.
Does Zydus Wellness Limited pay dividends?
Zydus Wellness Limited pays a Annually dividend of ₹1.2 which represents an annual dividend yield of 0.23%. See more information on Zydus Wellness Limited dividends here
What is Zydus Wellness Limited’s EPS estimate?
Zydus Wellness Limited’s EPS estimate is 0.4.
How many shares outstanding does Zydus Wellness Limited have?
Zydus Wellness Limited has 318,160,700 shares outstanding.
What happened to Zydus Wellness Limited’s price movement after its last earnings report?
Zydus Wellness Limited reported an EPS of ₹3.7 in its last earnings report, missing expectations of ₹3.933. Following the earnings report the stock price went down -1.894%.
Which hedge fund is a major shareholder of Zydus Wellness Limited?
Currently, no hedge funds are holding shares in IN:ZYDUSWELL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Zydus Wellness Limited
Zydus Wellness Limited is an Indian firm dedicated to the creation, manufacturing, promotion, and distribution of health and wellness products. Their extensive product range encompasses popular sugar substitutes such as Sugar Free Gold, Sugar Free Natura, and Sugar Free Green. The company also offers well-known beverages like Complan, a milk-based health drink, and Glucon D, a glucose-infused refreshment, alongside Sugarlite, a unique blend of sugar and stevia. In the personal care segment, Zydus Wellness markets the Everyuth brand, featuring skincare items such as soap-free face washes, masks, scrubs, and cleansers. The Nycil brand provides solutions for prickly heat, cooling powders, and hand sanitizers. Furthermore, their Nutralite line includes a diverse array of spreads, from probiotic butter and table spreads to ghee, butter, cholesterol-fat-free spreads, mayonnaise, and chocolate spreads. Beyond its domestic operations in India, Zydus Wellness actively exports its offerings. Tracing its origins to 1988, the Ahmedabad, India-based entity was initially known as Carnation Nutra Analogue Foods Limited before adopting its current name, Zydus Wellness Limited, in January 2009. It operates as a subsidiary of Cadila Healthcare Limited.
Technical Analysis
Adani Wilmar Limited
―
Britannia Industries Ltd
―
Nestle India Ltd.
―
Patanjali Foods Limited
―
Tata Consumer Products Limited
―